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                           INTRODUCTION 
 Cirrhosis liver, is characterized by diffuse destruction and 
regeneration of hepatic parenchymal cells leading to deposition of 
connective tissue with resulting disorganization of the lobular and vascular 
architecture. Despite the remarkable regenerative capacity of the liver, 
once hepatic parenchymal reserve is exceeded, clinically overt or 
decompensated cirrhosis ensues. Portal hypertension develops due to 
resistance to blood flow through the liver resulting increase in portal 
venous pressure leading to diversion of blood flow through low resistance 
portosystemic collaterals thereby bypassing the liver. 
 Hyperdynamic circulatory state is one of the manifestation of portal 
hypertension. The splanchnic vasodilatation is an important factor that 
promotes and maintains the portal hypertensive state. This in turn leads to 
activation of neurohumoral pathways that stimulate renal sodium retention, 
expansion of plasma volume and ultimately accumulation of ascitic fluid in 
persons with cirrhosis. 
 Expanded plasma volume also contributes to increase in portal 
blood flow and portal pressure. 
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 The current study was designed to precisely evaluate the 
cardiovascular system in a group of patients with hepatic cirrhosis based 
on clinical  examination, elctrocardiography, roentgenography  and M-
Mode  2-dimensional  echocardiography. 
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AIM OF THE STUDY 
1.To clinically evaluate patients with hepatic cirrhosis with respect to 
changes in heart rate, blood pressure, mean  arterial pressure, jugular 
venous pressure and precordial examination. 
 
2. To document the electrical and morphological alterations in the heart in 
patients with cirrhosis by means of non-invasive investigations like 
electrocardiography, roentghenography and M-Mode 2-Dimensional 
echocardiography. 
 
3. To determine the relationship between the cardiac and hemodynamic 
parameters and the severity and extent of hepatic cirrhosis. 
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                          RELATED STUDIES 
 Cirrhosis liver reflects irreversible chronic injury to the hepatic 
parenchyma characterized by extensive fibrosis, in association with the 
formation of regenerative nodules with resulting disorganization of the 
lobular and vascular architecture. Decompensated cirrhosis leads to portal 
hypertension and hepatocellular failure. 
 Hyperdynamic circulation more directly  suggests the presence of 
portal hypertention and hepatocellular failure. Various studies have been 
carried our over the years to evaluate the cardiac and hemodynamic 
changes in cirrhosis of liver. 
The studies done include : 
1956- Hecker R and Sherlock S showed that blood pressure is low in  
patients with heptacellular failure and in terminal phase it further reduces 
renal function. 
 
.1958 – Murray JF; Dawson, A.M and Sherlock – S also reported the 
presence of increased cardiac output and hyperdynamic circulation in 
patients with chronic liver disease. 
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1960 – Platt. D; Kie, F.E; Lubocinski HP; showed that cirrhotics are less 
liable for atheroma formation than the general population. 
 
1969 – Schaffner, Bull, found Over 50 patients of cirrhosis four had 
myocardial infarction and two had severe angina. 
 
1973 – Howel Wl, Manion WC ; reviewed 639 cases of cirrhosis at autopsy 
and found that incidence of myocardial infarction is about a quarter of that 
among total cases  examined without cirrhosis. 
 
1975 -  Lunzer MR, Newman SP; Sherlock S; demonstrated impaired 
cardiovascular responsiveness in liver disease. 1985 – Lenz K, Klein 
berger G; et al studied the circulatory behaviour in 26 patients with liver 
insufficiency and demonstrated significant increase in heart rate, stroke 
volume, cardiac index with decrease in diastolic pressure, and total 
peripheral resistance. 
 
1986 -  Braillon, Gut, Meng . J Gasthepatol, The magnitude of the 
hemodynamisc changes in the hyperkinetic state also correlates with the 
severity of cirrhosis by a modified Pugh’s classification. 
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1988 -  Shah, ArchIntMed, ascites with cirrhosis may also be associated 
with pericardial effusion.  
 
1988 – Minuk GY. MacCannel KC; postulated that decreasd hepatic 
clearance of GABA may play a note in pathophysiology of hypotension in 
cirrhotics. 
 
1989 – Kristev A, Mitkov D, studied the role of octanioc acid in the 
development of cardio vascular disorders occurring in some patients with 
liver disease associated with increased levels of octanoic acid. 
 
1989 – Henricksen J H, Bendtsen F, Sorensen T.A et al demonstrated 
reduced central blood volume  (heart, lungs and central arterial tree) in 
patients with cirrhosis liver. 
 
1991 -  Heikal, Hall, Lunseth, showed 9 percent of patients dying with 
cirrhosis had hypertensive heart disease.  
 
 14
1993 – Seina Y, Ohki K; et al studied 19 patients with cirrhosis liver and 
demonstrated decreased cutaneous  blood  flow in cirrhotic patients due to 
increase in arteriovenous anastomosis. 
 
1994 – Meng HC, Lin HC et al evaluated 193 patients with cirrhosis liver 
and demonstrated that the severity of cirrhosis is closely related to the 
degree of the hyperkinetic circulatory state and portal hypertension. 
 
1994 – Usha Srinivas, Mahadevan V.S et al evaluated 40  cases of 
cirrhosis liver by M-Mode and Doppler  echocardiography. 
 
1996 -  Lee SS proposed that the ventricular hypo responsiveness in 
cirrhotic patients may be due to cirrhotic cardiomyopathy. 
 
2001 – Moller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis.  
Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J 
Gastroenterol 2001, 36 : 785-794. 
 
2002 – Liu H, Song D, Lee SS. Cirrhotic cardiomyopathy, Gastroenterol 
Clin Biol 2002; 26 : 842 –847. 
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2005 – Moeper MM, Halank M, Marc C, Hoeffken G, Seyfarth HJ, Schauer 
J, Niedermeyer J, Winkler J, Bosentan portopulmonary hypertension. Eur 
Respir J 2005 ; 25 : 502-508. 
 
2006 – Sfner Moller, Jens H  Henriksen Cardiomyopathy complications in 
chronic liver disease. 
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OVER VIEW OF CIRRHOSIS LIVER 
 Cirrhosis is a pathologically defined entity which is associated with 
a spectrum of characteristic clinical manifestations. The cardinal 
pathologic features reflect irreversible chronic injury to the hepatic 
parenchyma and include extensive fibrosis in association with formation of 
regenerative nodules (fig;1). These features result from hepatocyte 
necrosis, collapse of the supporting reticular network with subsequent 
connective tissue deposition, distortion of the vascular  bed, and nodular 
regeneration of remaining liver parenchyma. Despite the remarkable 
regenerative capacity of the liver, once the hepatic parenchymal reserve is 
exceeded, clinically overt or decompensated cirrhosis ensues. 
CLASSIFICATION : 
1. Micro nodular cirrhosis: There is preponderance of parenchymal 
nodules that are less than 3 mm in diameter. There is involvement 
of every lobule. The micro nodular liver may represent impaired 
capacity for regrowth as in alcoholism, malnutrition, old age and 
anaemia. 
2.  Macro nodular cirrhosis : In this size of the nodules exceed more 
than 3 mm in diameter. Nodules are highly variable is size and 
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normal lobules are found amongst larger nodules. Regeneration is 
reflected by large cells with large nuclei and by cell plates of 
varying thickness eg. Post necrotic cirrhosis. 
3.  Mixed Cirrhosis : Combination of micro nodules and macro 
nodules eg. Biliary cirrhosis. 
 Most types of cirrhosis may be conveniently classified by a mixture 
of etiologically and morphologically defined entities as follows. 
1. Alcoholic 
2. Cryptogenic 
3.Post viral or post necrotic 
¾ Viral hepatitis [Hepatitis B, Non – A, Non – B. 
¾ Hepatitis D, hepatitis C, Cytomegalovirus) 
¾ Toxoplasmosis 
¾ Schistosomiasis 
¾ Ecchinococcus 
¾ Brucellosis 
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4. Inherited and Metabolic disorders : 
¾ Haemochromatosis 
¾ Wilson’s disease 
¾ Alpha 1 – antitrypsin deficiency  
¾ Galactosaemia 
¾ Glycogen storage disease 
¾ Gaucher’s disease 
¾ Hereditary fructose intolerance 
¾ Hereditary tyrosinemia 
¾ Fanconi’s syndrome 
5. Drugs and toxins : 
¾ Methyldopa 
¾ Methotrexate 
¾ Isoniazid 
¾ Perhexilene maleate 
¾ Oxyphenisatin 
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¾ Arsenicals 
¾ Oxyphenisatin 
¾ Arsenicals 
6. Biliary Cirrhosis : 
¾ Primary 
¾ Secondary 
¾ Hepatic venous outflow obstruction : 
¾ Budd Chiari Syndrome 
¾ Cardiac cirrhosis 
¾ Veno occlusive disease 
8. Miscelleneous : 
¾ Sarcoidosis 
¾ Graft Vs Host disease 
¾ Chronic inflammatory bowel disease 
¾ Cystic fibrosis 
¾ Jejunoileal bypass 
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¾ Diabetes mellitus 
¾ Carcinomatous cirrhosis 
¾ Indian childhood cirrhosis 
¾ Immunological – Lupoid hepatitis. 
Clinical And Biochemical Classification: 
 Clinical features of cirrhosis (fig :2) derive from the morphologic 
alterations and aften reflect the severity of liver damage rather  than the 
etiology of underlying liver disease. Loss of functioning hepatocellular 
mass may lead to jaundice, edema, coagulopathy, spider telangiectasia, 
palmar erythema, parotid and lacrimal gland enlargement , nail changes, 
Duputytren’s contractures, gynaecomastia, ascites, testicular atrophy as 
well as  confusion and asterexis suggesting hepatic encephalopathy. 
 Distorted vasculature leads to portal hypertension. Portal 
hypertension develops when resistance to blood flow through the liver, is 
increased and resulting increase in portal venous pressure lead to 
diversion of blood flow through low resistance portosystemic collaterals 
thereby bypassing the liver. Hyperdynamic circulation, caput medusae, 
splenomegaly and gastro esophageal varies more directly suggest the 
presence of portal hypertention. 
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                      Fig.1.FIBROSIS WITH NODULAR REGENERATION 
 
 
 
 
 
 
 
        
                          Fig.2.CLINICAL FEATURES OF CIRRHOSIS 
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Ascites and hepatic encephalopathy result from both  hepatocellular insufficiency 
and portal hypertension. 
Compensated Cirrhosis : 
 This stage is discovered by the following 
a) Early symptoms : 
¾ Vague abdominal pain 
¾ Fatigue 
¾ Mild pyrexia 
¾ Vascular spiders  (fig : 3) 
¾ Palmar erythema (fig : 4)  
¾ Unexplained epistaxis 
¾ Ankle oedema 
b) Detected on a routine check up 
¾ Firm non tender hepatosplenomegaly (fig : 5) 
¾ Elevated transaminases 
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Fig: 3 VASCULAR SPIDERSAND METHOD OF DEMONSTRAITON 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4  PALMAR ERYTHEMA  
 
 
 
` 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 25
c) Background 
¾ Alcoholism 
¾ Hepatitis 
¾ Decompensated Cirrhosis  
 The patient usually seeks medical advice because of ascites and/or 
jaundice. Features include poor general health, muscle wasting, weight 
loss. (fig: 6):Continuous mild fever (37.5 – 380C) is often due to gram 
negative bacteremia., to continuing  hepatic  cell necrosis or to a 
complicating liver cell carcinoma. Foetor hepaticus may be present. 
Cirrhosis is the commonest cause of hepatic encephalopathy. 
 Jaundice(fig : 7) implies that liver cell destruction exceeds the 
capacity of regeneration and deeper the jaundice, greater the inadequacy 
of the liver cell function. 
 The skin may be pigmented. Clubbing of fingers may be present. 
Purpura over the arms, shoulders and shins may be associated with a low 
platelet count. Spontaneous bruising and epistaxis reflect a prothrombin 
deficiency.  
 The circulation is overactive. The blood pressure is low. Sparse 
body hair, vascular spiders, palmar erythema, white nails (Leuconychia) 
and gonadal atrophy are common. 
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FIG : 5 : SPLENOMEGALY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG : 6 : DECOMPENSATED CIRRHOSIS 
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Ascites is usually preceded by abdominal distention edema of the legs is 
frequently seen (fig : 8) 
 The liver may be enlarged and firm or contracted and impalpable. 
Spleen may be palpable and firm. Hametological manifestations of 
cirrhosis include anemia, leukopenia and thrombocytopenia which may 
result from splenomegaly and hypersplenism. 
 A classification scheme based on a combination of several factors, 
the Child-Turcotte classification has been useful in estimating long term 
outcome which is represented below . 
CHILD TURCOTTE CLASSIFICATION OF SEVERITY OF CIRRHOSIS 
INDEX  CLASS  
 A B C 
Bilirubin (mg/dl) <2.0 2.0-3.0 >3.0 
Albumin (g/dl) >3.5 3-3.5 <3 
Ascites None Easily controlled Poorly 
Controlled 
Encephalopathy None Mild Advanced 
Nutritional 
Status 
Excellent Good Poor 
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FIG : 7 :  JAUNDICE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG : 8 :  ASCITES WITH EDAMA LEGS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 29
PATHOPHYSIOLOGY OF PORTAL HYPERTENSION : 
 The fundamental hemodynamic abnormality is an increased  
resistance to  portal blood flow. This may be intra hepatic as in cirrhosis or 
due to obstructed portal vein due to thrombosis. As the portal venous 
pressure is lowered by the development of collaterals deviating portal 
blood into systemic veins, the portal hypertention is maintained by 
increasing the blood flow in the portal system which thus becomes 
hyperdynamic. Resistance to portal blood flow is exerted along both the 
hepatic and portal collateral circulation and appears to be modified by 
vasoactive agents. Portal hypertension is defined as portal venous 
pressure exceeding 12 mm Hg. 
ROLE OF ULTRASOUND: 
 Ultrasonography has proved to be a useful non invasive and 
inexpensive method to establish the presence of and aetiology of portal 
hypertension. 
 A normal ultrasound shows the liver to have mixed echogenicity. In 
cirrhosis of the liver the edge of the liver may be irregular and the liver 
shows coarse echo pattern. It has a fine stippled echogenicity due to 
increased acoustic attenuation. In end stage cirrhosis the liver is small and 
very echogenic. It has a nodular border and may be outlined well by ascitic 
fluid. One portion of the liver may have a different echogenicity from the  
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FIG :  9 : COLLARERALS OVER THE 
ANTERIOR ABDOMINAL WALL 
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remainder and form a bulge.  This represents a regenerating nodule. 
Portal hypertension and splenomegarly are present. Caudate lobe is 
enlarged relative to the right lobe. 
 The presence of portal hypertension is sonologically assessed by 
the following features. 
1. Splenomegaly :  If the transducer has a 900 angle and the 
superior and inferior border of the spleen cannot fit on an image, 
the spleen is enlarged. Static scans are helpful if serial exams for 
splenomegaly are needed. To evaluate splenic size on a static scan 
a superior view is preferred. The spleen is enlarged when its 
anterior border lies in front of the aorta and inferior vena cava and it 
is at least as thick as a normal kidney. 
2. Portal vein dilated to >1.3cm. Estimation of portal vein and splenic 
vein diameter is useful to predict the presence of oesophageal 
varices. Portal vein and splenic vein size of 12 mm 8 mm are good 
predictors (93.05% and 94.89% respectively ) of oesophageal 
varices but their size did not differ significantly according to grade of 
varices. 
3. Recanalization of paraumbilical veins with in the  ligamentum teres.  
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4. Collaterals – Small tortuous vessels at porta hepatis gastric fundus, 
pancreatic beds splenic hilum – Doppler and colour flow detect 
vessels.  
5. Dilated splenic and superior mesenteric veins. 
6. Ascites 
7. Normal flow in the portal vein and hepatic artery is in the direction to 
the liver – Hepatopetal.  In severe portal hypertension flow in the 
portal vein is reversed towards the feet – hepatofugal. Color flow 
makes this change is direction obvious and Doppler cursor through 
both vessels simultaneously demonstrates the direction of flow. 
8. Fenestrated thickened gall bladdar wall is a unique 
ultrasonagraphic sign seen in patients with portal hypertention. This 
appearance is possible due to congestive thickness of the gall 
bladder wall with collaterals in the wall giving it a fenestrated 
appearance. 
ROLE OF ABDOMINAL PARACENTESIS : 
 Diagnostic paracentesis of about 50 ml is always performed in case 
of ascites. Complication like bowel perforation and hemorrhage may rarely 
occures in  patients with cirrhosis of liver after paracentesis. 
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 Protein concentration rarely exceeds 2.5 g/100 ml. Higher values 
suggest infection. If serum albumin to ascites albumin gradient (SAAG) is 
greater than 1.1 g/dl then it indicates presence of portal hypertension. The 
SAAG reflects a difference in the oncotic pressures and correlates well 
with the portal venous pressure. 
 Fluid usually appears straw coloured or clear and sometimes in 
advanced cirrhosis chylous ascites may result due to accumulation of 
chylomicrons on the ascitic fluid. 
 From 1950 onwards abdominal paracentesis was the accepted 
treatment of tense ascites. Seleciton criteria for the therapeutic 
paracentesis include. 
¾ Tense ascites preferably with edema 
¾ Child’s grade B 
¾ Prothrombin > 40 % 
¾ Serum Bilirubin <10 mg/dl 
¾ Platelets > 40,000/cu mm 
¾ Serum creatinine<3 mg /dl 
¾ Urinary sodium>10 mEq/24 hrs 
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Usually 5-10 litres of fluid is removed followed by replacement of salt poor 
albumin 1V 6g/litre of fluid removed. Single large paracentesis of about 10 
lts in 1 hour with intravenous salt poor albumin is also equally effective and 
safe. 
ROLE OF LIVER BIOPSY: 
Needle Biopsy of The liver : 
 Needle biopsy of the liver is indicated in the cirrhosis of liver in that 
it helps to confirm the diagnosis and may provide a clue for the aetiology 
of cirrhosis. Since the lesions in most cases of cirrhosis liver are diffuse, 
such a small biopsy specimen is representive of changes in the whole 
liver. 
 The exception to this is macro nodular cirrhosis in which aspiration 
often large nodule may reveal normal architecture. The diagnostic yield 
may be improved by three consecutive samples obtained by redirecting 
the biosy needle. 
Types of needles used : 
¾ Vim Silverman Needle 
¾ Menghini Needle 
Trucut needle : For the purpose of the study, the trucut needle was chosen 
because it is of value in cirrhosis patients as it caused less fragmentation. 
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Biopsty gun (BIOPTER) 
Surecut needle : 0.66 mm, May be used to diagnose cirrhosis when the 
Menghini needle is contraindicated. Risk of complication is minimal. 
Approach For liver Biopsy : 
1. Intercostal approach is the most frequent method and it rarely fails. 
2. Liver biopsy can also be performed via the transjugular route in 
patient with small liver, failed transcutaneous approach. Wedged 
and free hepatic venous pressure can be measured simultaneously. 
3. Direct (Guided) liver Biopsy 
4. Ultrasound or CT Scan guided liver biopsies give a higher 
percentage of positivity than the blind percutaneous techniques. 
Contraindications : 
• Coagulation defects 
• Platelet count less than 80,000/cu mm 
• Tense ascites 
• Very  small fibrotic liver 
• Known vascular lesions like hemangioma 
 
 36
Naked Eye Appearance : 
 A satisfactory biopsy is 1-4  cms long and weighs 10-50 mg. The 
cirrhotic liver tends to crumble into fragments of irregular contour. 
 The biopsy is usually fixed in 10% formal – saline. Routine stains 
include haematoxylin and eosin and a good stain for connective tissue. 
Orcein staining is useful to show hepatitis B surface in the hepatocyte; and 
is also an  indicator of cholestasis and Wilson’s disease. 
Microscopic Appearance : 
This is characterized by the following  : 
¾ Parenchymal injury and consequent diffuse fibrosis in the form of 
delicate bands (portal central, portal-portal, central – central) or 
broad scars replacing multiple adjacent lobule. 
¾ Reorganized vascular architecture. 
¾ Parenchymal nodules created by regeneration of hepatocytes. 
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PATHOPHYSIOLOGY OF CARDIAC AND CIRCULATORY CHANGES 
IN CIRRHOSIS LIVER 
CHAMBER DYNAMICS AND MYOCARDIAL FUNCTION  
 Chronic liver diseases like cirrhosis produce high cardiac output 
states. The mechanisms is uncertain but has been attributed to increased 
blood volume, intrahepatic arteriovenous shunts, mesenteric arteriovenous 
shunts and defects in inactivation of circulating vasodilators. 
 M-Mode 2-Dimenisonal echocardiography is a useful – invasive 
method of studying the various morphological and functional parameter. In  
patients with cirrhosis liver prior studies have shown that right ventricular 
end diastolic volume and right ventricular end systolic volume where 
significantly reduced in patients whereas left ventricular end diastolic 
volume and left ventricular end systolic volume and left atrial volume were 
normal or slightly increased. The right ejection fraction was significantly 
increased and the left ejection fraction was slightly decreased. Stroke 
volume was significantly greater. There is also evidence of myocardial 
contractile function impairment and ventricular hyporesponsiveness to 
pharmacological or physiological stress. Diastolic dysfunction was found to 
be 35% in prior studies and more common in alcoholic than in non 
alcoholics. These changes are  reversed following liver transplantation. 
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 Pericardial effusion has been demonstrated in  a significant number 
of patients and is seen as a echo free zone surrounding the heart and if 
large the whole heart can be seen swinging in to it. 
 Pulmonary hypertension was seen  in 12% of patients. 
 The incidence of coronary and aortic atheroma is less than the rest 
of the population. At autopsy, the incidence of myocardial infarction is 
about a quarter of that among total cases examined without cirrhosis. 
HAEMODYNAMIC CHANGES; 
Peripheral Vasodilation And Hyperkinetic Systemic Circulation: 
 Vasodilatation is characteristically shown by flushed extremities, 
bounding pulses and capillary pulsations. 
 The cardiac output is raised and this is evidence by resting 
tachycardia and active precordial impulse and frequent systolic murmur. 
The splenic blood flow is increased . The renal blood flow especially renal 
corical perfusion is reduced. Cutaneous micro circulation is reduced due to 
opening of arterio venous channels and neurohumoral factors. The cardiac 
index was significantly raised. 
 The mean arterial pressure and peripheral resistance are markedly 
reduced. The blood pressure is further lowered and is an ominous sign as 
it further reduces kidney function. Attempts to raise the circulatory volume 
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by blood transfusin or drugs such as dopamine are only of temporary 
benefit. 
 The systemic vascular peripheral resistance is reduced, as is the 
arteriovenous oxygen difference. In patients with cirrhosis whole body 
oxygen consumption is reduced and tissue oxidation is abnormal. This has 
been related to hyperdynamic circulation and to arterio venous shunting. 
Thus the vasodilatory state of liver failure may contribute to general tissue 
hypoxia. 
 Vasomotor tone is decreased as shown by reduced 
vasoconstriction in response to exercise, the Valsalva maneuver and tilting 
from horizontal to vertical posture. Pro bably the increased production of 
glucagon and other vasodilatory substances in portal hypertension leads 
to attenuated response to endogenous vasosontrictors which minimizes 
the systemic effects of activated neurohumoral systems.  
 The circulatory state is due to the opening up of  a large number of 
normally present but functionally inactive arteriovenous anastomoses that 
have opened under the influence of a vasodilator substance. The diseased 
liver might produce such a vasodilator or fail to metabolize one formed 
else where. 
 Peripheral vasodilation is thought to play a major role in the 
activation of neurohumoral systems leading to sodium  retention., 
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expansion of plasma volume and finally to the accumulation of ascites in 
patients with cirrhosis. The systemic circulation is therefore markedly 
vasodilated despite increased levels of endogenous vasoconstrictors 
because peripheral vasodilation is the stimulus that activates these 
endogenous vasoactive substances in an attempt to maintain the arterial 
blood pressure and systemic vascular resistance, there are vascular 
territories showing marked vasoconstriction such as femoral artery, cubital 
artery and renal artery. Thus it has been suggested that reversal of 
splanchnic   vasodilation could improve the renal perfusion in patients with 
cirrhosis, ascites and hepatorenal syndrome. 
 The nature of the vasodilator remains speculative. The agent 
responsible for hyperdynamic portal system is probably not the same as 
that causing systemic hyperdynamic state. 
 Gamma Amino Butyric Acid (GABA) is a candidate . It is a potent 
inhibitory neurotransmitter synthesized by the intestinal mucosa and by 
anaerobic bacteria in the gut. In advanced liver disease hepatic clearance 
of GABA is impaired and this might cause hypotension  by vascular 
smooth muscle relaxation. 
 Various gastrointestinal peptides such as VIP, Substance P and 
CGRP have little effect on the portal circulation Glucagon is a vasodilator 
and the plasma concentration increases in rats with portal hypertension. 
Glucagon is a powerful splanchnic vasodilator and it is markedly increased 
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in cirrhosis. Glucagon increases the azygos flow in patients with cirrhosis 
but has little effect on cardiac index or haemodynamics so implying little 
effect on systemic vascular resistance. 
 Prostaglandins (PGE1, PGE2, and PG12) have vasodilatory actions 
and prostanoids are released into the portal vein in patients with chronic 
liver disease. This may play a part in systemic vasodilatation. 
 In patients with chronic liver disease there is impairment of Kupffer 
cell function and intrahepatic shunting occurs with impaired clearance of 
endotoxin resulting in systemic endotoxaemia and bacteraemia. 
Endotoxaemia will result in activation of macro phages with release of TNF 
and interleukins whose circulating half life will also be increased in their 
face of hepatic dysfunction. The elevated levels of endotoxin and 
cytokines may be important  in the development of hemodynamic 
abnormalities in chronic liver disease with the expression of inducible nitric 
oxide synthase. High levels of nitric oxide – Endothelium Derived Relaxing 
Factor (EDRF) results in profound vasodilation. Nitric oxide inhibitors  
rapidly correct arterial hypotension and reduced systemic resistance. 
 Recently  octanoic acid has been proposed to play a role on the 
development of cardiovascular disorders. Occuring in some liver diseases 
associated with high octanoic acid levels in blood  serum. Octanoic acid 
has an   inotropic action thereby increasing the cardiac output. It also 
decrease arterial pressure and vascular resistance. These are inhibited by 
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indomethacin a fact suggesting that prostaglandin system plays a role in 
the mechanism of cardiovascular cation s of octanioc acid. This hypothesis 
represents a new concept regarding the pathogenesis of hyperdynamic 
cardio vascular syndrome in liver cirrhosis and hepatic encephalopathy. 
Table :  Circulatory changes in patients with cirrhosis : 
Increased Plasma/total blood volume  
Non-central blood volume Cardiac 
output 
portal pressure and flow 
Reduced Central blood volume 
 Arterial blood pressure splanchnic 
vascular resistance systemic 
vascular resistance Renal blood 
flow. 
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SPLANCHNIC VASODILATATION AND INCREASED PORTAL 
VENOUS INFLOW: 
 Increase portal venous inflow is characteristically observed in 
advanced stages of p0rtal hypertension. Increased portal blood flow is 
capable by itself in producing portal hypertension but likely acts to 
maintain or aggravate portal hypertension in addition to increases 
resistance. Increased portal venous inflow is the result of a marked 
arteriolar vasodilation in splanchnic organs draining into portal vein. Many 
different mechanisms have been suggested t explain the striking 
haemodynamic abnormality involving neurogenic, humoral and local 
mechanisms. 
 Several  studies have focussed on the potential role of circulating 
vasodilators. These vasodilators include neuropeptides, prostacyclin, 
adenosine, bile acids. Bile acids , ammonia, endotoxin, and a variety of 
vasodilatory gastrointestinal hormones. Other substances including 
neuropeptide, secretin, cholecystokinin, pancreatic polypeptide and 
estrogens may induce splanchnic vasodilation at pharmacological doses 
but not in the range observed under physiologic  conditions. 
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 Vasodilators Vasoconstrictors 
Renal Prostaglandin E2  
Nitric oxide 
 Kallikrein – kinin 
system Prostacyclin 
Endothelin-1 
Thromboxane A2 
Angiotensin II 
Leukotrienes 
Adenosine 
Systemic Nitric oxide 
 Atrial natruretic 
peptide 
Adrenomedullin 
Calcitonin gene-related 
peptide. 
AngiotensinII 
Noradrenaline 
Antidiuretic hormone 
Neuropeptide Y. 
 
 Glucagon is a powerful splanchnic vasodilator and accounts for 
30% to 40% of splanchnic vasodilation of chronic portal hypertension. 
Glucagon promotes vasodilation by a dual mechanism viz., relaxing the 
vascular  smooth muscle and decreasing the sensitivity to endogeneous 
vasoconstrictors like norepinephrine, Angiotensin II and Vasopressin. 
 The endogeneous has also been implicated in splanchnic 
vasodilation that develops after surgical portocaval shunts. 
 Studies have demonstrated diurnal variations in portal venous 
inflow with a maximal increase at night. This probably  accounts for the 
peak incidence of acute variceal bleeding during the night. 
 The significance of splanchnic vasodilatation and increased portal 
venous inflow is that most of the pharmacological agents used in the 
treatment of portal hypertension have been aimed at correcting this factor. 
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A. Splanchnic vasoconstrictors : 
1.Somatostatin and analogues (Octreotide) 
2. Beta adrenegic blockers. 
3. Vasopressin and analogues (Glypressin)  Propanolol 
 Tertatolol 
B. Vasodilators : 
  They reduce vascular resistance in the intrahepatic 
vasculature. 
 1. Organic nitrates  -  Isosorbide di nitrate 
      Isosorbide 5 mono nitrate 
 2. Clonidine  
 3. Calcium channel blocker - Verapamil 
      Nicardipine 
 4. Serotonin blockers  -  Ketanserin 
      Ritanserin 
 5. Molsidomine a venodilator -  
 6. Alpha adrenergic blocker - Prazosin. 
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C. Miscellaneous : 
 Reduce blood flow and pressure in gastrooesophagial variceal 
system  
1. Metoclopromide 
2. Domperidone 
3. Pentagastrin 
EXPANDED PLASMA VOLUME : 
 Increased plasma volume is a constant   finding  in portal 
hypertension. It is thought that the expansion of the plasma volume is due 
to transient sodium retention which in turn is triggered by peripheral 
vasodilatation. The expanded plasma volume thus represents a response 
directed to refill the dilated arterial vascular tree. Sequential studies have 
shown that hypertension, sodium retention and expansion of the plasma 
volume occur prior to the increase in cardiac output. It is likely that these 
expanded plasma volume plays a permissive role in the increase of 
cardiac index. 
 Recent studies also support the view that the increase in cardiac 
output in cirrhosis is primarily determined by an increase in the vascular 
volume and not due to arterial vasodilation. 
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 The expanded blood volume and hyperkinetic circulation allow a 
hemodynamic stabilization and no further sodium retention occurs. 
However when the disturbances are more pronounced and accompanied 
by increased Trans capillary albumin escape it is not possible to achieve 
such a hemodynamic compensation, and sodium retention continues, 
leading to the formation of ascites and edema. 
 Expansion of plasma volume therefore has a greater importance 
than what has been traditionally considered in the pathogenesis of 
circulatory disturbances in portal hypertension. Studies show that the 
reduction of plasma volume with low sodium and spironolactone 
represents another possible treatment  of portal hypertention. Which could 
be very appropriate combination therapy with treatments acting through 
different mechanisms. 
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SYSTEMIC HEMODYNAMIC FACTORS IN FORMATION OF ASCITES 
IN CIRRHOSIS LIVER WITH PORTAL HYPERTENSION 
 Cirrhosis accounts for 80% of cases of ascites. Various theories 
have been proposed to explain the pathogenesis of ascites of which the 
most recently proposed theory is as follows : 
THE PERIPHERAL ARTERIAL VASODILATATION HYPOTHESIS OF 
ASCITES FORMATION : 
 More recently, a hypothesis to account for the renal sodium and 
water retention and ascites formation in cirrhosis has been proposed. This 
hypothesis has characteristics of both the classical underfill and overflow 
theories. It suggests that peripheral arterial vasodilatation is the event that 
initiates sodium and water retention in cirrhosis. Peripheral vasodilatation 
initially results  in a moderate decrease in effective arterial blood volume 
that stimulates the release of neurohumoral mediators affecting the renal 
circulation and tubular function and promoting sodium and water retention, 
thus leading to plasma volume expansion and establishing a new 
equilibrium with  the return of the vasoactive factors to normal levels. As 
the peripheral vasodilatation becomes more severe, the neurohumorally  
mediated expansion of plasma volume is no longer adequate to fill the 
vascular space and the vasoactive control systems become chronically 
activated. As the liver disease becomes more severe, the abnormalities in 
the neruohumoral systems   
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The Perlpheral Arterial Dllatation Hypothesis of Ascites formation in 
patlents with cirrhosis. 
EABV – Effective Arterial Blood Volume      SNS : Sumpathetic Nervous 
System RAAS : Renin –angiotesin – aldosterone system      
AVP – Arginine Vasopressin 
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Impalred                                               Sinusoidal 
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become more profound and produce extreme change in renal 
haemodynamics abd tubular function which can lead to the development   
of the hepatorenal syndrome. 
MICROCIRCULATION IN CIRRHOSIS LIVER : 
 In patients with cirrhosis liver with acute episodes of 
decompensation there is disturbance of the microcirculation resulting in a 
tissue  oxygen debt that is greater in patients that fail to survive. In such 
patients the use of prostacyclin, a micro circulatory vasodilator results in 
an increase in the oxygen uptake with the possibility of lessening or 
reversing the covert oxygen debt. 
CIRRHOTIC CARDIOMYOPATHY : 
 In cirrhosis cardiac contractile function has been extensively 
documented to be abnormal. At baseline , cardiac output is increased as a 
result of hyperdynamic circulation but when challenged by 
pharmacological or physiological stress ventricular hyporesponsiveness is 
revealed. 
 This phenomenon has been termed “Cirrhotic Cardiomyopathy”. 
Diminished myocardial beta adrenergic receptor signal transduction 
function, possibly caused by a persistent elevation in norepinephrine 
content has been shown to play an important role. Alteration in cardiac 
plasma membrane properties due to impaired lipid metabolism is also 
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crucial. Other possible pathogenic factors proposed include accumulation 
of cardiodepressant substances caused by hepatocellular insufficiency 
and ventricular overload secondary to increased blood volume and 
hyperdynamic circulation. Because the cardiac reserve function is 
borderline in patients with cirrhosis, cardiovascular status should be 
carefully monitored, especially when the patients undergo stresses such 
as live transplantation or portosystemic shunting procedures. 
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      MATERIALS AND METHODS  
 The present study was conducted in the Thanjavur Medical College 
Hospital, between November 2005 and October 2006. 50 patients of 
cirrhosis liver were selected for the study. These patients were admitted in 
the general medical wards. 
Criteria followed for selection of patients included : 
1. Only patients with clinical, biochemical and sonographic evidence of 
cirrhosis liver were selected. 
2. Patients with previously detected heart disease were excluded from 
the study. 
3. Patients with inter current illness and those who were critically ill 
were excluded from the study. 
4. Patients with cardiac cirrhosis were excluded form the study. 
 A detailed history was elicited form the patient with special 
reference to cardiovascular symptoms. A thorough physical examination 
was performed in the patients and a special note was made regarding 
heart rate & rhythm, blood pressure, jugular venous pulse and pressure 
and precordial examination. 
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 All patients were subjected to routine investigations viz, Blood urea, 
sugar,  complete haemogram, serum cholestrol &  liver function tests. All 
patients were subjected to ultrasound scan abdomen to confirm the 
diagnosis of cirrhosis. Patients with ascites underwent abdominal 
paracentesis and fluid was analyzed for protein content and cells. All 
patients were then subjected to electrocardiography, chest X-ray and M-
mode 2-Dimensional echocardiography. 
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Cardiac Changes in Cirrhosis 
PROFORMA 
NAME :             AGE  SEX M  D.O.A 
OCCUPATION :   I.P.NO                   F             D.O.D 
        ALCOHOLIC                NON-ALCOHOLIC  
KNOWN CARDIAC PATIENT       YES / NO 
               COMPLAINTS  
 
ABDOMINAL PAIN       ABD MASS   JAUNDICE   
ABD DISTENTION     HAEMATEMESIS     
 
           CLINICAL FINDINGS  
 
JAUNDICE    HEPATOMEGALY     SPLENOMEGALY     
PEDAL OEDEMA              JVP       
PULSE :              BP :    MAP : 
 
     INVESTIGATIONS  
 
Hb :     Blood Sugar :     
Tc :     Blood Urea   : 
Dc :     Serum Creatinine : 
RBC :     Serum Electrolytes :         Na+ : 
PLATELETS:              K+   : 
PCV :     LET      Ascitic Fluid  
URINE  ALB :   Sr Bilirubin :   Analysis  
  SUG :   SGOT :   Glucose : 
  DEP :   SGPT :   Protein : 
     SAP : 
HBSAG :    Sr Protein : 
Sr. Ceruloplasmin :               Albumin : 
      Globulin  : 
 
ECG :       CXR : 
 
 
 
USG ABDOMEN :     OGD : 
 
 
 
ECHOCARDIOGRAM : 
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               RESULTS AND OBSERVATION 
 
 
 
 
 
 
 
           
 Out of the 50 patients studied 35 (70%) were males and 15 (30%) 
were females( fig : 9). The age of the patients ranged from 19 years to 75 
years. 
 
 
 
 
70%
30%
Male 70 %
Female 30 %
10%
78%
4%8% HBsAG 8%
DM 4%
Alcoholic 10 %
Others 78 %
  Fig : 9 
Fig : 10 
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 5 Patients (10%) were alcoholics, 14 patients (28%) had past 
history of jaundice or, 8 patients (16%) presented with haemetemesis         
(fig : 11) on admission  and 27 patients (54%) had  ascites, 9 patients 
(18%) had jaundice and 6 patients (12%) had clinically detectable 
splenomegaly on admission. Among this 4 patients were HbsAG+ (8%) 
and 2 patients were diabetics (4% (fig : 10). All patients had  sonographic 
evidence of cirrhosis.with portal hypertension . 
TYPES OF CLINICAL PRESENTATION : 
 
 
 
 
 
 
 Regarding the cardiovascular examination 20 (40 %) out of 50  
patients had symptoms referable to the heart table below : 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
HAEMETEMESIS ASCITES JAUNDICE SPLENOMEGALY
HAEMETEMESIS 16 %
ASCITES 54%
JAUNDICE 18%
SPLENOMEGALY 12 %
Fig : 11 
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CARDIOVASCULAR SYMPTOMS AND SIGNS 
1. SYMPTOMS PRESINT                 20 RANGE 
2. PULSE RATE 84/ min 54 to 120/min 
3. JVP ELEVATION 12 %             - 
4. BLOOD PRESSURE 
SYSTOLIC 
DIASTOLIC 
MAP 
 
110 mmHg 
70   mmHg 
84   mmHg 
 
 
90 to160 mmHG 
50 to 100 mmHG 
70 to 110 mmHG 
5. HEART MURMURS 6%            - 
6. CONGESTIVE CARDIAC 
    FAILURE 
6  %            - 
 3 Patients (6%) had congestive cardiac failure. The average pulse 
rate was 84 and it ranged form 54/m to 120/m. The jugular venous 
pressure was elevated in 6(12%) patients. The systolic blood pressure 
from ranged  90mmHg to 160 mmHg., the average being 110.mmHg. The 
diastolic blood pressure ranged from 50mmhg to 100 mmHg ., the average 
being 70 mmHg. The mean arterial pressure ranged from 70 mmHg to 110 
mmHg the average being 86 mmHg Functional high output systolic flow 
murmur was detected in 3 (6%)  patients.  
 Out of 50 patients 3 patients had elevated blood pressure. Previous 
studies shows that the systolic blood pressure more than 160mmHG and 
diastolic blood pressure more than 95 mmHg are the range for 
hypertension in cirrhorotic patients.  
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X-RAY CHEST IN ASCITES PATIENT 
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 The electro cardiac gram showed an average heart rate of 82 / m. 
The low QRS voltage in chest leads and limb leads were found in 10 
patients (fig :12). T  wave inversion was found in chest leads (V1 to V3 / V6) 
in  4 (8%) patients, in II, III avf in 7 patiens (14%). Regarding Hemiblock 2 
(4%) cases were observed in the study. qs complex in  anterior & Inferior 
leads is seen in 4 patients (8%). 
  The chest roentgenogram showed Hepatic Hydrothorax in 5 
patients (10%). Cardio megaly was evident in chest X – ray in 11 patients 
(22%) (fig :13). 
 M-Mode 2 Dimensional Echocardiographic studies , done showed 
abnormality in 15 (30%) patients. Pericardial effusion (fig : 14) was 
detected in 4(8%) patients. Regarding enlargement of cardiac chambers – 
all 4 chambers were enlarged in 3 (6%) patients. With global hypokinesia a 
nd left ventricular hypertrophy in 1 (2%) patient. One  case of  porto 
pulmonary HT was observed in our study (2 %). Akinesia of inferior and 
anterior  wall was seen in 4 (8%) patients (fig : 15) and hyperdynamic flow 
due to anemia was observed in 2 patients (4 %).  
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                      FIG.12.ECHO SHOWS MILD PERICARDIAL EFFUSION 
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DISCUSSION 
 The aetiology of cirrhosis in patient under study showed a slightly 
higher incidence of post hepatic or post necrotic cirrhosis as compared to 
western studies.  
 With regard to the cardiovascular evaluation, the average heart rate 
in present study was 84±2 beats per minute. Other studies  showed the 
average heart rate as follows. 
 Lenz K, Lleinberger G et al 1985  – 101 / min + 2 Vs 78 
 Bernard M, Rubbloli et al 1991  - 79/min + 2 Vs 71   
 McCormick P.A; Chin J et al  1995  - 101/min + 2 Vs 78 
 Present study 2006   - 84±2 / min Vs 74 
 Thus the present study confirms that there is an increase in heart 
rate in cirrhosis liver as compared to the average heart rate of healthy 
subjects, reflecting a hyper dynamic circulatory state. 
 The average systolic blood pressure, diastolic blood pressure and 
mean arterial pressure in the present study  were 110mm/Hg and 
70mm/Hg and 86mmHg respectively. In the other studies they were as 
follows: 
 66
 Lenz L; Kleinberger G et al 1985  - Diastolic pressure 56 Vs 
71. 
 McCormick PA, Chin H et al 1995 – 86 - Mean arterial pressure. 
 The present study shows that the  mean arterial pressure is 
comparable with that of the study done by McCormick P.A et al but the 
diastolic pressure is within the normal range. 
 The elevation of jugular venous pulse in 12% of patient reflects an 
increase in the plasma volume and fluid over load. Significant correlation 
was demonstrated between the heart rate and mean arterial pressure both 
of which indicate a hyper dynamic circulation and serum albumin and 
serum bilirubin levels both of which are indicators of liver dysfunction. The 
present study clearly demonstrated that hyperdynamic circulation 
progressively increase with the severity of the liver dysfuntion. The study 
quoted for this include Meng HG, Lin HC et al 1994 which also concludes 
that the severity of cirrhosis is closely related to the degree of hyperkinetic 
circulatory state and portal hypertension. Significant positive correlation 
was noted between decreased MAP in 36 % and increased HR in 54 %, 
similarly decreased serum albumin  in 32 % and increased serum bilirubin 
in 44%.  
 The present study shows that out of 50 patients 3 patients are 
hypertensive 6 %. 
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 Regarding the electrocardiographic findings not many studies are 
available showing the various electrocardiographic abnormalities in 
cirrhosis liver. It has been said that cardiac arrhythmias in cirrhosis liver 
are always due to a definable precipitating event such as hypo or hyper 
kalemia, acidosis, hypoxia or cardiac irritation due to insertion of lines, 
although in older patients the possiblility of ischemic heart disease must 
not be ignored. One study by Walt, Toyonaga A et al 1995 demonstrated 
that cardiac arrthythmias is common during surgery, the commonest 
arrhythmias being premature ventricular contration. The current study 
shows that low voltage QRS complexes were present in 10 patients. Out 
of which 4 had pericardial effusion probably reflecting the presence of 
occult pericardial effusion. T wave inversion was noted in the precordial 
leads & limb leads in 11 patients and CAHD changes in 4 Patients had no 
symptoms referable to the cardiac system.  
S.NO ECG  
ABNORMALITIES 
INCIDENCE 
N=24 
% 
48 
2 LOW VOLTAGE COMPLEXES 10 20 
3 CAHD / INFARCTION 
          ISCHEMIC CHANGES  
4 
10 
8 
20 
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 Chest roentgenograms showed that the elevated hemidiaphragms 
were the commonest abnormality detected and all these patients had 
ascites and the elevated hemidiaphragms probably reflecting increased 
intra-abdominal pressure. Cardiomegaly was detected in 11 patients. 
Hepatic Hydrothorax  was found in 5  patients. 
Chest roentgenograms  evaluation of patients under study is as 
follows : 
 
X- RAY CHANGES INCIDENCE 
N = 16 
% 
 
CARDIOMEGALY                 11                 22 
HEPATIC - 
HYDROTHORAX  
                 5                 10 
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Echocradiographic evaluation of patients under study is as follows : 
S.NO ECHO 
ABNORMALITIES 
INCIDENCE 
N = 15 
% 
30 
1 Cardiomyopathy  
Global hypokinesia & chamber 
enlargement present. 
           3 
( Out of 3, One 
patients is 
Alcoholic)  
            6 
2 Pericardial Effusion             4            8 
3 CAHD changes             5           10 
4 Porto Pulmonary HT            1            2 
5 Hyper dynamic Flow  due to 
anemia 
           2            4 
6 LV Dysfunction (LVEF<49%)            3 6 
             Moderate Anemia  < 10 g %, severe Anemia < 7 to 8 gm %                 
(fig : 16) 
52% 48%
0%
10%
20%
30%
40%
50%
60%
Moderate
Anemia
Severe
Anemia
Severe Anemia 48 %
Moderate Anemia 52 %
 
 Current study shows that all the 50 patients were anemic that is  < 
10 gm %. Among this 24 (48%) Patients were severely anemic and 26 
(52%) patients are moderately anemic.  
Fig : 16
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CONCLUSION 
1. The result of this study clearly show that large number of patients 
with hepatic cirrhosis are asymptomatic (40%) with regard to 
cardiovascular system, have evidence of cardiac involvement in  
elctrocardiography and echo cardiography.  
 
2. cardiac decompensation in cirrhosis is rare despite the high output 
state and its presence as indicated by left ventricular systolic 
dysfunction.. 
 
3. The incidence of hypertension  in cirrhosis patients, our study 
shows 3 patients ( 6 % ). 
 
4. Electrocardiographic abnormalities includes low voltage complexes 
due to pericardial effusion non specific T wave abnormalities and 
CAHD changes. 
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5. Cardiomyopathy, pericardial effusion, portopulmanary hypertension 
and CAHD are  the Echocardiographic abnor -malities detected in 
this study.  
 
6. All the patients were anemic, either the hyperdynamic circulation 
and hyperkinetic syndrom is due to cirrhosis or due to anemia is still 
in controversy. Further it needs a long term follow up and study.  
 
7. Cardiac evaluation is a pre-requisite in patients with cirrhosis 
undergoing stress like surgery because the presence of cardiac 
involvement adds to the morbidity and mortality.  
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S. 
No 
Name Age 
Sex 
I.P.No HR Sys 
BP 
Dias 
BP 
MAP Hb
% 
Sr. 
bil 
Sr. 
alb 
BLD 
Urea 
USG 
ABD 
1 Thangaiyan 40/M 912660 64 130 80 96 3.4 0.8 3.4 25 Cirrh /  
PHT 
2 Mathiyalagan 39/M 911255 98 100 70 80 6 0.1 2.8 37 Cirrh /  
PHT 
3 Mohammed Arif 74/M 905946 86 140 80 100 8.2 1.4 3 18 Cirrh /  
PHT 
4 Singaram 75/M 900079 88 120 80 94 6 1.4 4.1 35 Cirrh /  
PHT 
5. Rengasamy 60/M 900835 90 100 70 80 4.6 0.8 3.3 22 Cirrh /  
PHT 
6. Suresh 19/M 906333 76 110 70 84 9.2 1.6 3 16 Cirrh /  
PHT 
7 Sanmugam 52/M 889159 84 100 70 80 6.2 6.8 3.5 30 Cirrh /  
PHT 
8 Thanabal 46/M 908914 78 130 80 96 9 2.4 3 34 Cirrh /  
PHT 
9 Noornisha 27/F 908856 88 110 70 84 8.8 0.8 3.2 28 Cirrh /  
PHT 
10 Gandhi 55/M 886274 88 110 70 84 5 1 3.5 15 Cirrh /  
PHT 
11 Sarbon bee 48/F 889080 80 110 80 90 6.4 2 3.4 22 Cirrh /  
PHT 
12 Kumar 40/M 891767 88 120 80 94 8.5 1.2 2.5 53 Cirrh /  
PHT 
13 Baby 59/F 917/05 76 160 100 120 9.4 1 3.7 30 Cirrh /  
PHT 
14 Arumugam 30/F 882491 90 120 80 94 7.2 4 3 28 Cirrh /  
PHT 
15 Padma 30/F 884912 76 100 70 80 8 1.4 2.7 16 Cirrh /  
PHT 
16 Savithiri 58/F 886392 92 110 80 90 7.8 .9 2 39 Cirrh /  
PHT 
17 Sankar Ganesh 19/M 912983 86 120 70 86 7 1.4 3.4 32 Cirrh /  
PHT 
18 Indirani  47/F 902192 96 120 80 94 9.2 1 2.3 34 Cirrh /  
PHT 
19 Sivapakkiam 40/F 910114 88 110 70 83 6.8 1.4 3.3 41 Cirrh /  
PHT 
20 Govindaraj 50/M 908529 98 120 70 86 8 3.4 2.7 28 Cirrh /  
PHT 
21 Pandian 48/M 891563 80 180 100 126 10.2 1.8 3.1 34 Cirrh /  
PHT 
22 Elavarasan 28/M 910963 80 120 80 94 10.4 6 3 24 Cirrh /  
PHT 
23. Kathaiyan 40/M 908640 86 100 70 80 7.8 1.2 3.4 36 Cirrh /  
PHT 
24 Kala 55/F 912876 72 120 80 94 9 .8 3.2 52 Cirrh /  
PHT 
25 Muniyandi 50/M 876538 84 120 80 94 8 .9 3.2 55 Cirrh /  
PHT 
26 Arunachalam 45/M 875558 92 110 70 84 8 1.2 3.4 36 Cirrh /  
PHT 
27 Karuppaiya 49/M 874959 82 110 60 76 9 5.8 3 34 Cirrh /  
PHT 
28 Sivasubramanian 35/M 871943 74 160 96 113 9.2 1.4 2.8 36 Cirrh /  
PHT 
29. Moorthy 39/M 873618 86 100 70 80 5.8 .6 2.6 182 Cirrh /  
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PHT 
30. Govindaraj 65/M 908531 84 120 80 94 9.2 1.2 2.5 46 Cirrh /  
PHT 
31 Raman 47/M 873762 80 110 80 90 9.2 1.2 3.2 24 Cirrh /  
PHT 
32 Thaialnayaki 50/F 876185 80 130 80 96 8.2 1.4 2.7 17 Cirrh /  
PHT 
33 Uttharasu 45/M 870571 80 110 80 90 5.6 2.6 3 43 Cirrh /  
PHT 
34 Chandra 40/F 873928 92 110 70 84 8.6 0.8 2.7 21 Cirrh /  
PHT 
35 Arockia Mary 52/F 822340 80 140 70 84 8 0.8 3.5 33 Cirrh /  
PHT 
36 Selvamani 50/M 889086 84 110 80 90 4 0.8 2.8 38 Cirrh /  
PHT 
37 Selvaraj 42/M 878636 80 110 70 84 8.6 1 4 19 Cirrh /  
PHT 
38 Ragumansha 52/M 875559 98 100 80 86 6.4 1.6 2.8 23 Cirrh /  
PHT 
39 Rajavarman 51/M 877726 88 110 70 84 9.4 .6 2.3 40 Cirrh /  
PHT 
40 
Gokila 
40/F 877437 96 110 80 90 9.8 4 3 21 Cirrh /  
PHT 
41 Asaraf Nisha 35/F 878448 82 120 80 94 6.2 1.4 2.8 24 Cirrh /  
PHT 
42 Kaliaperumal 55/M 908750 84 120 80 94 9.2 0.8 3.3 30 Cirrh /  
PHT 
43 Mani 63/M 879311 88 120 70 86 2.8 .9 3.2 32 Cirrh /  
PHT 
44 Selvi  35/F 879846 80 110 70 84 7.6 1.2 2.6 94 Cirrh /  
PHT 
45 Yusuf 39/M 889008 96 110 70 84 7.2 8.2 3.4 18 Cirrh /  
PHT 
46 Samikannu 65/M 963142 98 120 80 94 6.4 3 2.4 56 Cirrh /  
PHT 
47 Malarkodi 30/F 884586 84 110 70 83 8.8 0.8 3.5 15 Cirrh /  
PHT 
48 Addaikklam 65/M 907865 86 110 80 90 9.2 .8 3.0 28 Cirrh /  
PHT 
49 Dhantayuthpani 53/M 909517 76 130 80 96 8.2 2.8 3.7 42 Cirrh /  
PHT 
50 Danial 60/M 901250 84 120 80 94 8.6 .8 3.5 36 Cirrh /  
PHT 
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